Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)

Key Inclusion Criteria: * Previous participation in Phase 1 Gilead clinical trial * Diagnosis of idiopathic pulmonary fibrosis * Females of childbearing potential and non-vasectomized males must agree to use highly effective methods of contraception * Females must discontinue nursing * Comply with study requirements * Have adequate organ function Key Exclusion Criteria: * History or evidence of clinically significant disorder, condition or disease that would pose a risk or interfere with the study * Pregnant or lactating * Clinically significant heart, hepatic or renal disease * History of cancer within 5 years of screening * Infection that is not controlled despite antibiotics or other treatment * History of bleeding diathesis within the last 6 months of Day 1 * Known history of human immunodeficiency virus, hepatitis B or C * Concern's for subjects compliance * Other conditions that might put the subject at high risk for treatment complications or reduce the chance to obtain data required * Placed on a lung transplant list * Previous participation in an idiopathic pulmonary fibrosis clinical trial other than for simtuzumab Note: Other protocol defined Inclusion/Exclusion criteria may apply